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Background: Hutchinson-Gilford progeria syndrome is a rare dominant human disease of genetic origin. The
average life expectancy is about 20 years, patients’ life quality is still very poor and no efficient therapy has yet been
developed. It is caused by mutation of the LMNA gene, which results in accumulation in the nuclear membrane of
a particular splicing form of Lamin-A called progerin. The mechanism by which progerin perturbs cellular
homeostasis and leads to the symptoms is still under debate.
Micro-RNAs are able to negatively regulate transcription by coupling with the 3’ UnTranslated Region of messenger
RNAs. Several Micro-RNAs recognize the same 3’ UnTranslated Region and each Micro-RNA can recognize multiple
3’ UnTranslated Regions of different messenger RNAs. When different messenger RNAs are co-regulated via a similar
panel of micro-RNAs, these messengers are called Competing Endogenous RNAs, or ceRNAs.
The 3’ UnTranslated Region of the longest LMNA transcript was analysed looking for its ceRNAs. The aim of this
study was to search for candidate genes and gene ontology functions possibly influenced by LMNA mutations that
may exert a role in progeria development.
Results: 11 miRNAs were isolated as potential LMNA regulators. By computational analysis, the miRNAs pointed to
17 putative LMNA ceRNAs. Gene ontology analysis of isolated ceRNAs showed an enrichment in RNA interference
and control of cell cycle functions.
Conclusion: This study isolated novel genes and functions potentially involved in LMNA network of regulation that
could be involved in laminopathies such as the Hutchinson-Gilford progeria syndrome.
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Lamins are intermediate filament proteins associated
with the inner nuclear membrane and are structural
components of the nuclear lamina. Interestingly, they
can also be found in the nucleoplasm, where they might
have regulatory functions that are still poorly investi-
gated [1-3]. Lamins are structural components of the
nuclear membrane, but they are also essential for many
nuclear functions [1,3]. Lamins can bind to specific
DNA sequences, chromatin modifications, and chroma-
tin associated proteins or complexes either directly or
through lamin-interacting proteins [1-4]. It has been
reported that lamin functions are involved in transcrip-
tional regulation, DNA replication and repair, epigenetic* Correspondence: carla.giordano@unipa.it
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reproduction in any medium, provided the ormodifications, chromatin remodelling, and transition
between euchromatin and heterochromatin conformation
[1,3,4]. Lamins are present in almost all pluricellular organ-
isms, with the exception of plants, and are usually absent
in unicellular organisms [5,6]. Generally, lamins are divided
into types A and B. In humans, A-type lamins are divided
into A and C lamins, both derived by alternative splicing
from the LMNA gene [5,6]. Interestingly, in humans, stem
cells and undifferentiated cells seem to lack Lamin-A and
Lamin-C. In this perspective, LMNA expressed lamins
behave as markers of differentiation [7].
The Hutchinson-Gilford progeria Syndrome (HGPS) is
a very rare human disease of genetic origin that leads to
very severe premature ageing. HGPS is caused by several
mutations in the LMNA gene, the most common of
which is the point mutation C1824T, which leads to the
accumulation in the nuclear membrane of a rare splicing
form of the Lamin-A called “progerin”, and alterationsl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bubbling, the cytological hallmark of HGPS [8]. The
accumulation of progerin is due to the impossibility of
physiological cleavage of the mature wild type Lamin-A
protein. Usually, Lamin-A is farnesylated and incorpo-
rated into the nuclear membrane, and later is cleaved
and released from the nuclear lamina. The classical
mutation in HGPS enhances the activity of a cryptic
splicing site that increases the production of progerin
and lessens the production of Lamin-A [8,9], acting as a
dominant mutation. Progerin lacks the cleavage site, so
the protein is farnesylated and loaded into the
membrane but cannot be removed efficiently any more,
so it accumulates [8,10]. It is to be noted that progerin
physiologically accumulates in the cells of ageing indivi-
duals, with a positive correlation with chronological age
[9-11]. HGPS affected individuals have a life expectancy
of about twenty years and a very poor quality of life [12].
No efficient healing therapy has yet been developed
and the main focus of current pharmacological strat-
egies is on farnesylation inhibitors that lessen the
progerin load in the nuclear membrane [10]. Though
an amelioration of the symptoms has been reported,
farnesylation inhibitors have not led to a definitive
solution [10]. The mechanism by which progerin
accumulation perturbs cellular homeostasis and leads to
the symptoms is still under debate [10]. The aim of this
study was to look for candidate genes and gene ontology
functions influenced by LMNA mutations that in turn
may have a role in progeria development.
The ceRNA (competing endogenous RNAs) hypothesis
is based on the rationale that RNA molecules can
regulate one another via microRNAs (miRNAs or miRs)
and that messengers RNAs (mRNAs) can be positively
co-regulated if they share miRNA target sequences
amongst their 3’UnTranslated regions (3’UTR), becauseTable 1 Predicted miRNAs that hit LMNA 3'UTR mRNA





LMNA NM_170707 hsa-miR-539 hsa-mir-539 10 2490
LMNA NM_170707 hsa-miR-671-5p hsa-mir-671 10 2553
LMNA NM_170707 hsa-miR-214 hsa-mir-214 9 2780
LMNA NM_170707 hsa-miR-9 hsa-mir-9-1 9 2544
LMNA NM_170707 hsa-miR-637 hsa-mir-637 9 2828
LMNA NM_170707 hsa-miR-298 hsa-mir-298 9 2600
LMNA NM_170707 hsa-miR-34a hsa-mir-34a 8 2709
LMNA NM_170707 hsa-miR-342-5p hsa-mir-342 8 3183
LMNA NM_170707 hsa-miR-449a hsa-mir-449a 8 2709
LMNA NM_170707 hsa-miR-532-3p hsa-mir-532 8 2933
LMNA NM_170707 hsa-miR-608 hsa-mir-608 8 2838there is a limited amount of miRNAs within each cell,
and each mRNA can act as a quencher for shared miRNAs
[13]. Following this rationale, genes whose mRNAs
share miRNAs targets in their 3’UTRs might be post-
transcriptionally co-regulated. For a more exhaustive
description of ceRNA rationale see [2,13]. The study
reported on here follows another study [2] on LMNA
interactome. This study focuses on an analysis of the
Lamin-A ceRNAs network of interactions.
Methods
Using the miRWalk [14] database for predicted gene
targets, miRNAs of a minimum of 7 matching nucleotides
on the longest human LMNA transcript 3’UTR with a
maximum p value of 0.05 were isolated. The settings
chosen were the standard settings for the software used
[14]. The 3’UTR analysed is the same in Lamin-A and
progerin transcripts; the 3’ UTR of Lamin-C is shorter
and different, and not included in this study. The work
was performed on predicted gene targets because there
are no validated targets reported for LMNA transcripts in
the miRWalk database. The miRNAs considered as
putatively recognizing the 3’UTR of the LMNA mRNA
were 11 and reported in Table 1. Table 1 also shows a
mimiRNA analysis [15] of the compared expression
profiles of LMNA and each miRNA in human tissues and
cell lines collected in the database. The set of miRNAs in
Table 1 was inserted into the miRWalk [14] MicroRNA
validated targets analysing tool to discover any human
gene mRNA 3’UTR that has been reported to have been
recognized by any of them. The genes isolated and the
related bait miRNAs are shown in Table 2. The genes
collected were organized in a hierarchical order for the
number of validated microRNA hits (Table 3). The more
microRNAs are shared between the 3’UTR of the longest





GGAGAAAUUA 2481 3 UTR 0.0010 −0.499 0.081
AGGAAGCCCU 2544 3 UTR 0.0010 −0.212 0.093
ACAGCAGGC 2772 3 UTR 0.0038 0.131 0.37
UCUUUGGUU 2536 3 UTR 0.0038 −0.133 0.32
ACUGGGGGC 2820 3 UTR 0.0038 −0.675 0.066
AGCAGAAGC 2592 3 UTR 0.0038 no results no results
UGGCAGUG 2702 3 UTR 0.0151 0.26 0.0071
AGGGGUGC 3176 3 UTR 0.0151 −0.212 0.093
UGGCAGUG 2702 3 UTR 0.0151 no results no results
CCUCCCAC 2926 3 UTR 0.0151 0.851 0.032
AGGGGUGG 2831 3 UTR 0.0151 −0.757 0.0138
Table 2 miRNAs that hit LMNA 3’UTR: their validated targets
MicroRNA name StemLoopName miR_Chr. Gene name EntrezID Pubmed ID
hsa-miR-9 hsa-mir-9-1 1 PRDM1 639 20966935
hsa-miR-9 hsa-mir-9-1 1 TP73 7161 18842901
hsa-miR-9 hsa-mir-9-1 1 MAPK3 5595 19958814
hsa-miR-9 hsa-mir-9-1 1 RAB34 83871 19531230
hsa-miR-9 hsa-mir-9-3 15 TP53 7157 19549897
hsa-miR-9 hsa-mir-9-1 1 TLR4 7099 19289835
hsa-miR-9 hsa-mir-9-1 1 SLC27A4 10999 20634564
hsa-miR-9 hsa-mir-9-1 1 DICER1 23405 18442408
hsa-miR-9 hsa-mir-9-1 1 NPAT 4863 18997113
hsa-miR-9 hsa-mir-9-1 1 FZR1 51343 20173740
hsa-miR-9 hsa-mir-9-1 1 CDC14A 8556 19956200
hsa-miR-9 hsa-mir-9-1 1 HRB 3267 16831872
hsa-miR-9 hsa-mir-9-1 1 FOXP1 27086 21248104
hsa-miR-9 hsa-mir-9-1 1 SOX2 6657 20947512
hsa-miR-9 hsa-mir-9-1 1 CDK6 1021 18768788
hsa-miR-9 hsa-mir-9-1 1 CDKN1A 1026 19956200
hsa-miR-9 hsa-mir-9-1 1 HDAC9 9734 19521961
hsa-miR-9 hsa-mir-9-1 1 C1orf61 10485 19289835
hsa-miR-9 hsa-mir-9-1 1 SIRT1 23411 20634564
hsa-miR-9 hsa-mir-9-1 1 RNASEN 29102 18442408
hsa-miR-9 hsa-mir-9-1 1 DICER1 23405 18997113
hsa-miR-9 hsa-mir-9-1 1 CDH1 999 20173740
hsa-miR-9 hsa-mir-9-1 1 CCNE1 898 19956200
hsa-miR-9 hsa-mir-9-1 1 EDG6 8698 16831872
hsa-miR-9 hsa-mir-9-1 1 FGF8 2253 21238922
hsa-miR-9 hsa-mir-9-1 1 LIN28 79727 20947512
hsa-miR-9 hsa-mir-9-1 1 E2F3 1871 18768788
hsa-miR-9 hsa-mir-9-1 1 CHEK1 1111 19956200
hsa-miR-9 hsa-mir-9-1 1 REST 5978 19458943
hsa-miR-9 hsa-mir-9-1 1 KRAS 3845 19137007
hsa-miR-9 hsa-mir-9-1 1 CREB1 1385 20624818
hsa-miR-9 hsa-mir-9-1 1 BACE1 23621 18434550
hsa-miR-9 hsa-mir-9-1 1 ELAVL2 1993 21368052
hsa-miR-9 hsa-mir-9-1 1 ELSPBP1 64100 18997113
hsa-miR-9 hsa-mir-9-1 1 BRCA1 672 20167074
hsa-miR-9 hsa-mir-9-1 1 CCNF 899 19956200
hsa-miR-9 hsa-mir-9-1 1 TRPM3 80036 16736490
hsa-miR-9 hsa-mir-9-1 1 TP53 7157 21238922
hsa-miR-9 hsa-mir-9-1 1 E2F1 1869 20930934
hsa-miR-9 hsa-mir-9-1 1 MYC 4609 18768788
hsa-miR-9 hsa-mir-9-1 1 ETS1 2113 19956200
hsa-miR-9 hsa-mir-9-1 1 MPI 4351 19406203
hsa-miR-9 hsa-mir-9-1 1 MAPK3 5595 19137007
hsa-miR-9 hsa-mir-9-1 1 REST 5978 20624818
hsa-miR-9 hsa-mir-9-1 1 CDKN2D 1032 18410378
hsa-miR-9 hsa-mir-9-1 1 ELAVL1 1994 21368052
hsa-miR-9 hsa-mir-9-1 1 PMP22 5376 18987208
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-9 hsa-mir-9-1 1 NFKB1 4790 20102618
hsa-miR-9 hsa-mir-9-1 1 CCNE2 9134 19956200
hsa-miR-9 hsa-mir-9-1 1 COL9A1 1297 16718610
hsa-miR-9 hsa-mir-9-1 1 SLC22A3 6581 21109969
hsa-miR-9 hsa-mir-9-1 1 MYC 4609 20930934
hsa-miR-9 hsa-mir-9-1 1 TGIF2 60436 18768788
hsa-miR-9 hsa-mir-9-1 1 ATF6 22926 19956200
hsa-miR-9 hsa-mir-9-1 1 CD46 4179 19330006
hsa-miR-9 hsa-mir-9-1 1 REST 5978 19137007
hsa-miR-9 hsa-mir-9-1 1 IGFALS 3483 20616011
hsa-miR-9 hsa-mir-9-1 1 DNMT1 1786 18314617
hsa-miR-9 hsa-mir-9-1 1 FOXG1 2290 21368052
hsa-miR-9 hsa-mir-9-1 1 PXMP2 5827 18987208
hsa-miR-9 hsa-mir-9-1 1 FOXO1 2308 20028871
hsa-miR-9 hsa-mir-9-1 1 KIF23 9493 19956200
hsa-miR-9 hsa-mir-9-1 1 SOAT1 6646 16357340
hsa-miR-9 hsa-mir-9-1 1 SOX2 6657 21109969
hsa-miR-9 hsa-mir-9-1 1 CEBPA 1050 20806079
hsa-miR-9 hsa-mir-9-1 1 PRDM1 639 18583325
hsa-miR-9 hsa-mir-9-1 1 EIF2C1 26523 19956200
hsa-miR-9 hsa-mir-9-1 1 NR2E1 7101 19330006
hsa-miR-9 hsa-mir-9-1 1 REST 5978 19118166
hsa-miR-9 hsa-mir-9-1 1 STMN1 3925 20616011
hsa-miR-9 hsa-mir-9-1 1 ROS1 6098 17629564
hsa-miR-9 hsa-mir-9-1 1 MEIS2 4212 21368052
hsa-miR-9 hsa-mir-9-1 1 ERBB2 2064 18973228
hsa-miR-9 hsa-mir-9-1 1 BDNF 627 19958814
hsa-miR-9 hsa-mir-9-1 1 CDC25A 993 19956200
hsa-miR-9 hsa-mir-9-1 1 STAT3 6774 21385897
hsa-miR-9 hsa-mir-9-1 1 PROM1 8842 21109969
hsa-miR-9 hsa-mir-9-1 1 CEBPB 1051 20806079
hsa-miR-9 hsa-mir-9-1 1 ATN1 1822 18583325
hsa-miR-9 hsa-mir-9-1 1 PAK3 5063 19956200
hsa-miR-9 hsa-mir-9-1 1 IFNG 3458 19289835
hsa-miR-9 hsa-mir-9-1 1 RCOR1 23186 19118166
hsa-miR-9 hsa-mir-9-1 1 STMN1 3925 20362537
hsa-miR-9 hsa-mir-9-1 1 FMR1 2332 17379214
hsa-miR-9 hsa-mir-9-1 1 PAX6 5080 21368052
hsa-miR-9 hsa-mir-9-1 1 MYC 4609 18973228
hsa-miR-9 hsa-mir-9-1 1 EPHB2 2048 19958814
hsa-miR-9 hsa-mir-9-1 1 NFKB1 4790 19702828
hsa-miR-9 hsa-mir-9-1 1 CBX7 23492 18686603
hsa-miR-9 hsa-mir-9-1 1 APC 324 21060828
hsa-miR-9 hsa-mir-9-1 1 DDIT3 1649 20806079
hsa-miR-9 hsa-mir-9-1 1 COMP 1311 18573151
hsa-miR-9 hsa-mir-9-1 1 ANLN 54443 19956200
hsa-miR-9 hsa-mir-9-1 1 IL1B 3553 19289835
hsa-miR-9 hsa-mir-9-1 1 BCL2 596 19118166
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-9 hsa-mir-9-1 1 MYC 4609 20173743
hsa-miR-9 hsa-mir-9-1 1 FOXG1 2290 17260156
hsa-miR-9 hsa-mir-9-1 1 NR2E1 7101 21368052
hsa-miR-9 hsa-mir-9-1 1 NTRK3 4916 18973228
hsa-miR-9 hsa-mir-9-1 1 GRIA1 2890 19958814
hsa-miR-9 hsa-mir-9-1 1 FZR1 51343 19572217
hsa-miR-9 hsa-mir-9-2 5 FRAP1 2475 20022054
hsa-miR-9 hsa-mir-9-1 1 RASSF1 11186 21060828
hsa-miR-9 hsa-mir-9-1 1 MYD88 4615 19289835
hsa-miR-9 hsa-mir-9-1 1 HMOX1 3162 20806079
hsa-miR-9 hsa-mir-9-1 1 GHRHR 2692 18573151
hsa-miR-9 hsa-mir-9-1 1 POU2F2 5452 19956200
hsa-miR-9 hsa-mir-9-1 1 RUNX1 861 19114653
hsa-miR-9 hsa-mir-9-1 1 MYC 4609 20173740
hsa-miR-9 hsa-mir-9-1 1 CREB1 1385 17002790
hsa-miR-9 hsa-mir-9-1 1 SLC7A5 8140 21368052
hsa-miR-9 hsa-mir-9-1 1 FOXG1 2290 18842901
hsa-miR-9 hsa-mir-9-1 1 GRIN2A 2903 19958814
hsa-miR-9 hsa-mir-9-1 1 CDH1 999 19572217
hsa-miR-9 hsa-mir-9-2 5 VEGFA 7422 20022054
hsa-miR-9 hsa-mir-9-1 1 FZR1 51343 21060828
hsa-miR-9 hsa-mir-9-1 1 NFKB1 4790 19289835
hsa-miR-9 hsa-mir-9-1 1 ROS1 6098 20806079
hsa-miR-9 hsa-mir-9-1 1 CHRD 8646 18573151
hsa-miR-9 hsa-mir-9-1 1 BCL6 604 19956200
hsa-miR-9 hsa-mir-9-1 1 IL1B 3553 19008124
hsa-miR-9 hsa-mir-9-1 1 MYCN 4613 20173740
hsa-miR-9 hsa-mir-9-1 1 REST 5978 17002790
hsa-miR-9 hsa-mir-9-1 1 GSX2 170825 21368052
hsa-miR-9 hsa-mir-9-1 1 BCL6 604 20966935
hsa-miR-9 hsa-mir-9-1 1 NEUROD1 4760 18842901
hsa-miR-9 hsa-mir-9-1 1 GRIN2B 2904 19958814
hsa-miR-9 hsa-mir-9-1 1 GRB2 2885 19531230
hsa-miR-9 hsa-mir-9-2 5 LARP6 55323 20022054
hsa-miR-9 hsa-mir-9-1 1 TLR2 7097 19289835
hsa-miR-9 hsa-mir-9-1 1 RPE 6120 20806079
hsa-miR-9 hsa-mir-9-1 1 NOG 9241 18573151
hsa-miR-9 hsa-mir-9-1 1 WEE1 7465 19956200
hsa-miR-9 hsa-mir-9-1 1 MMP13 4322 19008124
hsa-miR-9 hsa-mir-9-1 1 VEGFA 7422 20173740
hsa-miR-9 hsa-mir-9-1 1 ZNF828 283489 17002790
hsa-miR-9 hsa-mir-9-1 1 SIRT1 23411 21288303
hsa-miR-671-5p hsa-mir-671 7 FASN 2194 20497147
hsa-miR-671-5p hsa-mir-671 7 IGF1 3479 20497147
hsa-miR-671-5p hsa-mir-671 7 IL6 3569 20497147
hsa-miR-671-5p hsa-mir-671 7 NFKB1 4790 20497147
hsa-miR-671-5p hsa-mir-671 7 RELB 5971 20497147
hsa-miR-608 hsa-mir-608 10 EIF2C1 26523 19851984
Arancio et al. Journal of Clinical Bioinformatics 2013, 3:2 Page 5 of 22
http://www.jclinbioinformatics.com/content/3/1/2
Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-608 hsa-mir-608 10 RNASEN 29102 19138993
hsa-miR-608 hsa-mir-608 10 XPO5 57510 20732906
hsa-miR-608 hsa-mir-608 10 EIF2C2 27161 19851984
hsa-miR-608 hsa-mir-608 10 DGCR8 54487 19138993
hsa-miR-608 hsa-mir-608 10 TARBP2 6895 20732906
hsa-miR-608 hsa-mir-608 10 GEMIN4 50628 19851984
hsa-miR-608 hsa-mir-608 10 XPO5 57510 19138993
hsa-miR-608 hsa-mir-608 10 PIWIL1 9271 20732906
hsa-miR-608 hsa-mir-608 10 DGCR8 54487 19851984
hsa-miR-608 hsa-mir-608 10 TARBP2 6895 19138993
hsa-miR-608 hsa-mir-608 10 DICER1 23405 16505370
hsa-miR-608 hsa-mir-608 10 C1orf183 55924 19851984
hsa-miR-608 hsa-mir-608 10 PIWIL1 9271 19138993
hsa-miR-608 hsa-mir-608 10 IL6 3569 21209110
hsa-miR-608 hsa-mir-608 10 MAP3K12 7786 19851984
hsa-miR-608 hsa-mir-608 10 DICER1 23405 20732906
hsa-miR-608 hsa-mir-608 10 SCPEP1 59342 21209110
hsa-miR-608 hsa-mir-608 10 GEMIN4 50628 19138993
hsa-miR-608 hsa-mir-608 10 RNASEN 29102 20732906
hsa-miR-608 hsa-mir-608 10 CD44 960 21149267
hsa-miR-608 hsa-mir-608 10 DDX20 11218 19138993
hsa-miR-608 hsa-mir-608 10 GEMIN4 50628 20732906
hsa-miR-608 hsa-mir-608 10 CDC42 998 21149267
hsa-miR-608 hsa-mir-608 10 DICER1 23405 19138993
hsa-miR-608 hsa-mir-608 10 DDX20 11218 20732906
hsa-miR-608 hsa-mir-608 10 DICER1 23405 19851984
hsa-miR-608 hsa-mir-608 10 EIF2C1 26523 19138993
hsa-miR-608 hsa-mir-608 10 EIF2C1 26523 20732906
hsa-miR-608 hsa-mir-608 10 HUWE1 10075 19851984
hsa-miR-608 hsa-mir-608 10 EIF2C2 27161 19138993
hsa-miR-608 hsa-mir-608 10 DGCR8 54487 20732906
hsa-miR-539 hsa-mir-539 14 KIT 3815 21273305
hsa-miR-539 hsa-mir-539 14 MITF 4286 21273305
hsa-miR-539 hsa-mir-539 14 HLCS 3141 20592104
hsa-miR-539 hsa-mir-539 14 LRPAP1 4043 16973894
hsa-miR-532-3p hsa-mir-532 X RUNX3 864 19336521
hsa-miR-532-3p hsa-mir-532 X CDKN2D 1032 19771204
hsa-miR-449a hsa-mir-449a 5 TP53 7157 20948989
hsa-miR-449a hsa-mir-449a 5 WISP2 8839 19351815
hsa-miR-449a hsa-mir-449a 5 MAPK8 5599 20859756
hsa-miR-449a hsa-mir-449a 5 HDAC9 9734 19252524
hsa-miR-449a hsa-mir-449a 5 C9orf127 51754 20859756
hsa-miR-449a hsa-mir-449a 5 HDAC1 3065 19252524
hsa-miR-449a hsa-mir-449a 5 RBBP6 5930 20485546
hsa-miR-449a hsa-mir-449a 5 E2F5 1875 19056356
hsa-miR-449a hsa-mir-449a 5 TP53 7157 20485546
hsa-miR-449a hsa-mir-449a 5 LAMC2 3918 19056356
hsa-miR-449a hsa-mir-449a 5 TP73 7161 20485546
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-449a hsa-mir-449a 5 LMX1A 4009 19056356
hsa-miR-449a hsa-mir-449a 5 CKAP4 10970 20485546
hsa-miR-449a hsa-mir-449a 5 ELSPBP1 64100 19056356
hsa-miR-449a hsa-mir-449a 5 DGCR8 54487 20485546
hsa-miR-449a hsa-mir-449a 5 CDK6 1021 19833767
hsa-miR-449a hsa-mir-449a 5 SERPINE1 5054 21375729
hsa-miR-449a hsa-mir-449a 5 SERPINE1 5054 20356416
hsa-miR-449a hsa-mir-449a 5 CDC25A 993 19833767
hsa-miR-449a hsa-mir-449a 5 CCND1 595 20948989
hsa-miR-449a hsa-mir-449a 5 PRKAR1A 5573 19351815
hsa-miR-449a hsa-mir-449a 5 HDAC1 3065 20948989
hsa-miR-449a hsa-mir-449a 5 WNT1 7471 19351815
hsa-miR-34a* hsa-mir-34a 1 CDKN2A 1029 19396864
hsa-miR-34a* hsa-mir-34a 1 HGF 3082 19396864
hsa-miR-34a* hsa-mir-34a 1 JUN 3725 19396864
hsa-miR-34a* hsa-mir-34a 1 NF2 4771 19396864
hsa-miR-34a* hsa-mir-34a 1 PDGFA 5154 19396864
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21225432
hsa-miR-34a hsa-mir-34a 1 COL2A1 1280 20675358
hsa-miR-34a hsa-mir-34a 1 ATP6V1B2 526 20144220
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 19167416
hsa-miR-34a hsa-mir-34a 1 CD44 960 19714243
hsa-miR-34a hsa-mir-34a 1 HOXA5 3202 14697198
hsa-miR-34a hsa-mir-34a 1 TIMM8A 1678 21051724
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 20428827
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19921694
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 18755897
hsa-miR-34a hsa-mir-34a 1 JAK2 3717 17976522
hsa-miR-34a hsa-mir-34a 1 CREB1 1385 19461653
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17554337
hsa-miR-34a hsa-mir-34a 1 CCNE2 9134 19461653
hsa-miR-34a hsa-mir-34a 1 MGST1 4257 21216258
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20598588
hsa-miR-34a hsa-mir-34a 1 ZEB1 6935 20037478
hsa-miR-34a hsa-mir-34a 1 AKT1 207 19029026
hsa-miR-34a hsa-mir-34a 1 HMGA2 8091 18803879
hsa-miR-34a hsa-mir-34a 1 VEGFA 7422 18320040
hsa-miR-34a hsa-mir-34a 1 KRAS 3845 20978195
hsa-miR-34a hsa-mir-34a 1 SLC12A1 6557 20420713
hsa-miR-34a hsa-mir-34a 1 JAG1 182 19398721
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20881002
hsa-miR-34a hsa-mir-34a 1 MET 4233 18834857
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21182263
hsa-miR-34a hsa-mir-34a 1 SMARCA5 8467 20439489
hsa-miR-34a hsa-mir-34a 1 BNIP3L 665 20018759
hsa-miR-34a hsa-mir-34a 1 CCND1 595 18823940
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 18677110
hsa-miR-34a hsa-mir-34a 1 CCND3 896 18406353
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 CDC25A 993 21321636
hsa-miR-34a hsa-mir-34a 1 SCPEP1 59342 20883704
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20185821
hsa-miR-34a hsa-mir-34a 1 VEGFA 7422 19293812
hsa-miR-34a hsa-mir-34a 1 ARCN1 372 21224215
hsa-miR-34a hsa-mir-34a 1 IL1B 3553 20675358
hsa-miR-34a hsa-mir-34a 1 IFNG 3458 20130213
hsa-miR-34a hsa-mir-34a 1 MITF 4286 19167416
hsa-miR-34a hsa-mir-34a 1 NOTCH1 4851 19714243
hsa-miR-34a hsa-mir-34a 1 MECP2 4204 14697198
hsa-miR-34a hsa-mir-34a 1 MET 4233 21051724
hsa-miR-34a hsa-mir-34a 1 RB1 5925 20428827
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19890883
hsa-miR-34a hsa-mir-34a 1 BBC3 27113 18755897
hsa-miR-34a hsa-mir-34a 1 MYB 4602 17976522
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 19461653
hsa-miR-34a hsa-mir-34a 1 BCL2 596 17554199
hsa-miR-34a hsa-mir-34a 1 CDC25C 995 19461653
hsa-miR-34a hsa-mir-34a 1 NFE2L2 4780 21216258
hsa-miR-34a hsa-mir-34a 1 FOXP1 27086 20598588
hsa-miR-34a hsa-mir-34a 1 FRAP1 2475 20018759
hsa-miR-34a hsa-mir-34a 1 TIMM8A 1678 19029026
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17914404
hsa-miR-34a hsa-mir-34a 1 HNF4A 3172 20018894
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20978195
hsa-miR-34a hsa-mir-34a 1 TCF21 6943 20420713
hsa-miR-34a hsa-mir-34a 1 NDUFA2 4695 19398721
hsa-miR-34a hsa-mir-34a 1 BCL2 596 20466628
hsa-miR-34a hsa-mir-34a 1 RGS3 5998 18834857
hsa-miR-34a hsa-mir-34a 1 YY1 7528 21182263
hsa-miR-34a hsa-mir-34a 1 JARID1B 10765 20439489
hsa-miR-34a hsa-mir-34a 1 BRAP 8315 20018759
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 18823940
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18677110
hsa-miR-34a hsa-mir-34a 1 CDC25A 993 18406353
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 21321636
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20868483
hsa-miR-34a hsa-mir-34a 1 NR1H4 9971 20185821
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19258450
hsa-miR-34a hsa-mir-34a 1 E2F5 1875 19461653
hsa-miR-34a hsa-mir-34a 1 HDAC2 3066 21224215
hsa-miR-34a hsa-mir-34a 1 NOS2A 4843 20675358
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 20089965
hsa-miR-34a hsa-mir-34a 1 MYC 4609 19167416
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19714243
hsa-miR-34a hsa-mir-34a 1 POU4F2 5458 14697198
hsa-miR-34a hsa-mir-34a 1 MITF 4286 21051724
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20428827
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 19773441
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 18719384
hsa-miR-34a hsa-mir-34a 1 PRB1 5542 17976522
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17554199
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19584398
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 21216258
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 20581456
hsa-miR-34a hsa-mir-34a 1 SSSCA1 10534 20018759
hsa-miR-34a hsa-mir-34a 1 MET 4233 19029026
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21399872
hsa-miR-34a hsa-mir-34a 1 OCA2 4948 20388802
hsa-miR-34a hsa-mir-34a 1 TNRC6A 27327 20976148
hsa-miR-34a hsa-mir-34a 1 VEGFA 7422 20420713
hsa-miR-34a hsa-mir-34a 1 WNT1 7471 19398721
hsa-miR-34a hsa-mir-34a 1 MET 4233 20466628
hsa-miR-34a hsa-mir-34a 1 CCNE2 9134 18834857
hsa-miR-34a hsa-mir-34a 1 CTNNBIP1 56998 21182263
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20439489
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 19960022
hsa-miR-34a hsa-mir-34a 1 MYC 4609 18823940
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18633110
hsa-miR-34a hsa-mir-34a 1 ING2 3622 18451145
hsa-miR-34a hsa-mir-34a 1 TIMM8A 1678 21321636
hsa-miR-34a hsa-mir-34a 1 IFNG 3458 20857148
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20185821
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19221490
hsa-miR-34a hsa-mir-34a 1 HMGA2 8091 17976522
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 19461653
hsa-miR-34a hsa-mir-34a 1 LOX 4015 21224215
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20675358
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20089965
hsa-miR-34a hsa-mir-34a 1 MYCN 4613 19167416
hsa-miR-34a hsa-mir-34a 1 PROM1 8842 19714243
hsa-miR-34a hsa-mir-34a 1 PTEN 5728 14697198
hsa-miR-34a hsa-mir-34a 1 ZNF135 7694 21047409
hsa-miR-34a hsa-mir-34a 1 FOXO1 2308 20424141
hsa-miR-34a hsa-mir-34a 1 MET 4233 19773441
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18719384
hsa-miR-34a hsa-mir-34a 1 HMGA2 8091 17554199
hsa-miR-34a hsa-mir-34a 1 MYB 4602 19584398
hsa-miR-34a hsa-mir-34a 1 SPI1 6688 21211043
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20581456
hsa-miR-34a hsa-mir-34a 1 DDIT4 54541 20018759
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19029026
hsa-miR-34a hsa-mir-34a 1 STMN1 3925 12554860
hsa-miR-34a hsa-mir-34a 1 SLC2A1 6513 20388802
hsa-miR-34a hsa-mir-34a 1 SCPEP1 59342 20976148
hsa-miR-34a hsa-mir-34a 1 SEMA6A 57556 20420713
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 ST3GAL4 6484 19372595
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20466628
hsa-miR-34a hsa-mir-34a 1 MAPK14 1432 20212154
hsa-miR-34a hsa-mir-34a 1 FOXJ1 2302 21088493
hsa-miR-34a hsa-mir-34a 1 AKT1 207 20433755
hsa-miR-34a hsa-mir-34a 1 E2F1 1869 19960022
hsa-miR-34a hsa-mir-34a 1 NOTCH1 4851 18823940
hsa-miR-34a hsa-mir-34a 1 BCL2 596 18505919
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18451145
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21321636
hsa-miR-34a hsa-mir-34a 1 CCND1 595 20734047
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20170545
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 19221490
hsa-miR-34a hsa-mir-34a 1 CD19 930 17934639
hsa-miR-34a hsa-mir-34a 1 MDM4 4194 19461653
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21224215
hsa-miR-34a hsa-mir-34a 1 GRM3 2913 20675101
hsa-miR-34a hsa-mir-34a 1 ATN1 1822 20086228
hsa-miR-34a hsa-mir-34a 1 PTEN 5728 19167416
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19421141
hsa-miR-34a hsa-mir-34a 1 BDNF 627 14697198
hsa-miR-34a hsa-mir-34a 1 ZNF77 58492 21047409
hsa-miR-34a hsa-mir-34a 1 PROM1 8842 20424141
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19773441
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 18711402
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17540599
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 19643983
hsa-miR-34a hsa-mir-34a 1 KLF4 9314 21211043
hsa-miR-34a hsa-mir-34a 1 TCL1A 8115 20581456
hsa-miR-34a hsa-mir-34a 1 HMG2L1 10042 20018759
hsa-miR-34a hsa-mir-34a 1 BCL2 596 18942116
hsa-miR-34a hsa-mir-34a 1 DDX20 11218 12554860
hsa-miR-34a hsa-mir-34a 1 PEA15 8682 20388802
hsa-miR-34a hsa-mir-34a 1 CEBPA 1050 20889924
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20386864
hsa-miR-34a hsa-mir-34a 1 BCL2 596 19347736
hsa-miR-34a hsa-mir-34a 1 FASN 2194 20213410
hsa-miR-34a hsa-mir-34a 1 MYC 4609 20212154
hsa-miR-34a hsa-mir-34a 1 CDC20B 166979 21088493
hsa-miR-34a hsa-mir-34a 1 BCL2 596 20433755
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19960022
hsa-miR-34a hsa-mir-34a 1 HELLS 3070 18823940
hsa-miR-34a hsa-mir-34a 1 MYCN 4613 18505919
hsa-miR-34a hsa-mir-34a 1 MYCN 4613 18504438
hsa-miR-34a hsa-mir-34a 1 MYC 4609 21297663
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 20734047
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20150330
hsa-miR-34a hsa-mir-34a 1 MYC 4609 19211792
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 SOAT1 6646 17934639
hsa-miR-34a hsa-mir-34a 1 MET 4233 19461653
hsa-miR-34a hsa-mir-34a 1 VEGFA 7422 21224215
hsa-miR-34a hsa-mir-34a 1 PHGDH 26227 20675101
hsa-miR-34a hsa-mir-34a 1 IL1B 3553 20086228
hsa-miR-34a hsa-mir-34a 1 ZEB1 6935 19167416
hsa-miR-34a hsa-mir-34a 1 AKT1 207 19115258
hsa-miR-34a hsa-mir-34a 1 CXCL12 6387 14697198
hsa-miR-34a hsa-mir-34a 1 RUNX2 860 21042576
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20424141
hsa-miR-34a hsa-mir-34a 1 ZAP70 7535 19717645
hsa-miR-34a hsa-mir-34a 1 MDM4 4194 18711402
hsa-miR-34a hsa-mir-34a 1 BIRC3 330 17540599
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19643983
hsa-miR-34a hsa-mir-34a 1 LEF1 51176 21211043
hsa-miR-34a hsa-mir-34a 1 CISH 1154 20548288
hsa-miR-34a hsa-mir-34a 1 ARIH2 10425 20018759
hsa-miR-34a hsa-mir-34a 1 BCL6 604 18942116
hsa-miR-34a hsa-mir-34a 1 EIF2C2 27161 12554860
hsa-miR-34a hsa-mir-34a 1 E2F1 1869 20889924
hsa-miR-34a hsa-mir-34a 1 NOTCH1 4851 20351093
hsa-miR-34a hsa-mir-34a 1 MCL1 4170 19347736
hsa-miR-34a hsa-mir-34a 1 LIN28 79727 19211792
hsa-miR-34a hsa-mir-34a 1 HES1 3280 20213410
hsa-miR-34a hsa-mir-34a 1 MAPKAPK2 9261 20212154
hsa-miR-34a hsa-mir-34a 1 AKT1 207 21067862
hsa-miR-34a hsa-mir-34a 1 NFKB1 4790 20433755
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 19960022
hsa-miR-34a hsa-mir-34a 1 SLC11A1 6556 18823940
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18497571
hsa-miR-34a hsa-mir-34a 1 BBC3 27113 18941118
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21297663
hsa-miR-34a hsa-mir-34a 1 TIMM8A 1678 20734047
hsa-miR-34a hsa-mir-34a 1 DDX4 54514 20150330
hsa-miR-34a hsa-mir-34a 1 SOCS1 8651 17934639
hsa-miR-34a hsa-mir-34a 1 MYB 4602 19461653
hsa-miR-34a hsa-mir-34a 1 HDAC9 9734 21224215
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20627091
hsa-miR-34a hsa-mir-34a 1 BCL2 596 20049626
hsa-miR-34a hsa-mir-34a 1 ZEB2 9839 19167416
hsa-miR-34a hsa-mir-34a 1 PIK3CA 5290 19115258
hsa-miR-34a hsa-mir-34a 1 VAMP2 6844 14697198
hsa-miR-34a hsa-mir-34a 1 PPARG 5468 21042576
hsa-miR-34a hsa-mir-34a 1 ERBB4 2066 20420713
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 19701195
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18711402
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17540598
hsa-miR-34a hsa-mir-34a 1 MYC 4609 19696787
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 21205967
hsa-miR-34a hsa-mir-34a 1 RPS19 6223 20548288
hsa-miR-34a hsa-mir-34a 1 BBC3 27113 20018759
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 18942116
hsa-miR-34a hsa-mir-34a 1 GEMIN4 50628 12554860
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 20889924
hsa-miR-34a hsa-mir-34a 1 CCND1 595 20309880
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19347736
hsa-miR-34a hsa-mir-34a 1 LARP4 113251 20144220
hsa-miR-34a hsa-mir-34a 1 MYCN 4613 19199973
hsa-miR-34a hsa-mir-34a 1 HDAC9 9734 20213410
hsa-miR-34a hsa-mir-34a 1 CSF1 1435 14697198
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 21067862
hsa-miR-34a hsa-mir-34a 1 PAWR 5074 20433755
hsa-miR-34a hsa-mir-34a 1 CDC20B 166979 19960022
hsa-miR-34a hsa-mir-34a 1 CYP2A6 1548 18780894
hsa-miR-34a hsa-mir-34a 1 MDC1 9656 18497571
hsa-miR-34a hsa-mir-34a 1 BAX 581 18941118
hsa-miR-34a hsa-mir-34a 1 TLR4 7099 21266501
hsa-miR-34a hsa-mir-34a 1 FASN 2194 20734047
hsa-miR-34a hsa-mir-34a 1 BCL2 596 17894887
hsa-miR-34a hsa-mir-34a 1 SFRS2 6427 19461653
hsa-miR-34a hsa-mir-34a 1 MAP1LC3A 84557 21224215
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 20606648
hsa-miR-34a hsa-mir-34a 1 E2F1 1869 20049626
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19074876
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19115258
hsa-miR-34a hsa-mir-34a 1 UBL4A 8266 14697198
hsa-miR-34a hsa-mir-34a 1 BAMBI 25805 21042576
hsa-miR-34a hsa-mir-34a 1 KCNMA1 3778 20420713
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19701195
hsa-miR-34a hsa-mir-34a 1 EPHB2 2048 18704095
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 17297439
hsa-miR-34a hsa-mir-34a 1 NOL3 8996 19696787
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21205967
hsa-miR-34a hsa-mir-34a 1 COX8A 1351 20508945
hsa-miR-34a hsa-mir-34a 1 DKK2 27123 20018759
hsa-miR-34a hsa-mir-34a 1 NOTCH1 4851 18942116
hsa-miR-34a hsa-mir-34a 1 RNPC3 55599 12554860
hsa-miR-34a hsa-mir-34a 1 ACSL1 2180 21366874
hsa-miR-34a hsa-mir-34a 1 NFYC 4802 20889907
hsa-miR-34a hsa-mir-34a 1 MET 4233 20309880
hsa-miR-34a hsa-mir-34a 1 SEC24D 9871 19336450
hsa-miR-34a hsa-mir-34a 1 CNN3 1266 20144220
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19167416
hsa-miR-34a hsa-mir-34a 1 DLL1 28514 20213410
hsa-miR-34a hsa-mir-34a 1 EZH2 2146 14697198
hsa-miR-34a hsa-mir-34a 1 PIK3CA 5290 21067862
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 RNASEN 29102 20433755
hsa-miR-34a hsa-mir-34a 1 CD47 961 19952055
hsa-miR-34a hsa-mir-34a 1 PPIG 9360 18780894
hsa-miR-34a hsa-mir-34a 1 STK39 27347 18497571
hsa-miR-34a hsa-mir-34a 1 MET 4233 19006648
hsa-miR-34a hsa-mir-34a 1 MAP3K9 4293 21266077
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20734047
hsa-miR-34a hsa-mir-34a 1 E2F1 1869 17894887
hsa-miR-34a hsa-mir-34a 1 HMGA2 8091 19461653
hsa-miR-34a hsa-mir-34a 1 MDM2 4193 21217645
hsa-miR-34a hsa-mir-34a 1 MYC 4609 20606648
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 20049626
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 19074875
hsa-miR-34a hsa-mir-34a 1 ACTB 60 18835850
hsa-miR-34a hsa-mir-34a 1 NOTCH1 4851 17150773
hsa-miR-34a hsa-mir-34a 1 CRIM1 51232 21042576
hsa-miR-34a hsa-mir-34a 1 LOX 4015 20420713
hsa-miR-34a hsa-mir-34a 1 BCL2 596 19697704
hsa-miR-34a hsa-mir-34a 1 GRM7 2917 18704095
hsa-miR-34a hsa-mir-34a 1 PTEN 5728 16762633
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20689156
hsa-miR-34a hsa-mir-34a 1 ZAP70 7535 21205967
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20470934
hsa-miR-34a hsa-mir-34a 1 TBK1 29110 20018759
hsa-miR-34a hsa-mir-34a 1 ZEB2 9839 18942116
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19158830
hsa-miR-34a hsa-mir-34a 1 BCR 613 21323860
hsa-miR-34a hsa-mir-34a 1 APC 324 20883704
hsa-miR-34a hsa-mir-34a 1 EPHB2 2048 20299489
hsa-miR-34a hsa-mir-34a 1 WNT1 7471 19336450
hsa-miR-34a hsa-mir-34a 1 BCL2 596 20687223
hsa-miR-34a hsa-mir-34a 1 EIF2C4 192670 20144220
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 19167416
hsa-miR-34a hsa-mir-34a 1 DICER1 23405 20019750
hsa-miR-34a hsa-mir-34a 1 G6PD 2539 14697198
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 21067862
hsa-miR-34a hsa-mir-34a 1 BCL2 596 20428827
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19948396
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 18755897
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17996645
hsa-miR-34a hsa-mir-34a 1 CDK4 1019 19461653
hsa-miR-34a hsa-mir-34a 1 CD44 960 21240262
hsa-miR-34a hsa-mir-34a 1 E2F3 1871 17894887
hsa-miR-34a hsa-mir-34a 1 CAV1 857 19461653
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21217645
hsa-miR-34a hsa-mir-34a 1 VEGFA 7422 20606648
hsa-miR-34a hsa-mir-34a 1 RB1 5925 20049626
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19074875
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 BCL2 596 18803879
hsa-miR-34a hsa-mir-34a 1 BCL2 596 17656095
hsa-miR-34a hsa-mir-34a 1 CDKN2A 1029 20978195
hsa-miR-34a hsa-mir-34a 1 PTPN13 5783 20420713
hsa-miR-34a hsa-mir-34a 1 BCL2 596 19683563
hsa-miR-34a hsa-mir-34a 1 PTPN12 5782 16762633
hsa-miR-34a hsa-mir-34a 1 IRS1 3667 18834857
hsa-miR-34a hsa-mir-34a 1 ANP32B 10541 21205967
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20470934
hsa-miR-34a hsa-mir-34a 1 MYBL1 4603 20018759
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18834855
hsa-miR-34a hsa-mir-34a 1 PTEN 5728 18704095
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 18406353
hsa-miR-34a hsa-mir-34a 1 PPP1R13L 10848 21323860
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20883704
hsa-miR-34a hsa-mir-34a 1 MAP2K1 5604 20299489
hsa-miR-34a hsa-mir-34a 1 AXIN2 8313 19336450
hsa-miR-34a hsa-mir-34a 1 TP53 7157 21240262
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 20687223
hsa-miR-34a hsa-mir-34a 1 ELK3 2004 20144220
hsa-miR-34a hsa-mir-34a 1 PRMT5 10419 19167416
hsa-miR-34a hsa-mir-34a 1 BCL2 596 19714243
hsa-miR-34a hsa-mir-34a 1 DLL1 28514 14697198
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 21051724
hsa-miR-34a hsa-mir-34a 1 E2F1 1869 20428827
hsa-miR-34a hsa-mir-34a 1 COL11A2 1302 19921694
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18755897
hsa-miR-34a hsa-mir-34a 1 HBEGF 1839 17976522
hsa-miR-34a hsa-mir-34a 1 CDK6 1021 19461653
hsa-miR-34a hsa-mir-34a 1 TP53 7157 17875987
hsa-miR-34a hsa-mir-34a 1 RNMT 8731 19461653
hsa-miR-34a hsa-mir-34a 1 GABPA 2551 21216258
hsa-miR-34a hsa-mir-34a 1 NDRG1 10397 20606648
hsa-miR-34a hsa-mir-34a 1 TP53 7157 20049626
hsa-miR-34a hsa-mir-34a 1 MCL1 4170 19074875
hsa-miR-34a hsa-mir-34a 1 TP53 7157 18803879
hsa-miR-34a hsa-mir-34a 1 SYNE1 23345 18258830
hsa-miR-34a hsa-mir-34a 1 COX8A 1351 20978195
hsa-miR-34a hsa-mir-34a 1 SFRP1 6422 20420713
hsa-miR-34a hsa-mir-34a 1 TP53 7157 19443717
hsa-miR-34a hsa-mir-34a 1 ECD 11319 12812784
hsa-miR-34a hsa-mir-34a 1 TOM1 10043 18834857
hsa-miR-34a hsa-mir-34a 1 BBC3 27113 21205967
hsa-miR-34a hsa-mir-34a 1 LIF 3976 20439489
hsa-miR-34a hsa-mir-34a 1 CREBZF 58487 20018759
hsa-miR-34a hsa-mir-34a 1 SIRT1 23411 18834855
hsa-miR-34a hsa-mir-34a 1 CDKN1A 1026 18677110
hsa-miR-34a hsa-mir-34a 1 CCND1 595 18406353
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-34a hsa-mir-34a 1 RTEL1 51750 21323860
hsa-miR-34a hsa-mir-34a 1 SND1 27044 20883704
hsa-miR-34a hsa-mir-34a 1 MET 4233 20190569
hsa-miR-34a hsa-mir-34a 1 NPC1 4864 19293812
hsa-miR-342-5p hsa-mir-342 14 ERBB2 2064 19432961
hsa-miR-342-5p hsa-mir-342 14 CCPG1 9236 18700954
hsa-miR-342-5p hsa-mir-342 14 ERBB2 2064 21172025
hsa-miR-342-5p hsa-mir-342 14 BCL2 596 19284987
hsa-miR-342-5p hsa-mir-342 14 GULP1 51454 18700954
hsa-miR-342-5p hsa-mir-342 14 EGFR 1956 20818338
hsa-miR-342-5p hsa-mir-342 14 IRAK2 3656 19284987
hsa-miR-342-5p hsa-mir-342 14 IRAK2 3656 18508790
hsa-miR-342-5p hsa-mir-342 14 KRAS 3845 20818338
hsa-miR-342-5p hsa-mir-342 14 IRF1 3659 19151778
hsa-miR-342-5p hsa-mir-342 14 JAK2 3717 18508790
hsa-miR-342-5p hsa-mir-342 14 IL1B 3553 20716963
hsa-miR-342-5p hsa-mir-342 14 IRF9 10379 19151778
hsa-miR-342-5p hsa-mir-342 14 HMGA2 8091 18508790
hsa-miR-342-5p hsa-mir-342 14 IRAK1 3654 20716963
hsa-miR-342-5p hsa-mir-342 14 TRIM63 84676 19151778
hsa-miR-342-5p hsa-mir-342 14 BCL2 596 17260024
hsa-miR-342-5p hsa-mir-342 14 MECP2 4204 20716963
hsa-miR-342-5p hsa-mir-342 14 CDKN1B 1027 18708351
hsa-miR-342-5p hsa-mir-342 14 NFKB1 4790 17260024
hsa-miR-342-5p hsa-mir-342 14 CD4 920 20448109
hsa-miR-342-5p hsa-mir-342 14 ERBB2 2064 18708351
hsa-miR-342-5p hsa-mir-342 14 CD4 920 19954774
hsa-miR-342-5p hsa-mir-342 14 SSSCA1 10534 18708351
hsa-miR-342-5p hsa-mir-342 14 IL2RA 3559 19954774
hsa-miR-342-5p hsa-mir-342 14 TACSTD1 4072 18700954
hsa-miR-342-5p hsa-mir-342 14 IL7R 3575 19954774
hsa-miR-342-5p hsa-mir-342 14 MEST 4232 18700954
hsa-miR-298 hsa-mir-298 20 BACE1 23621 20375468
hsa-miR-298 hsa-mir-298 20 CYP3A4 1576 19581388
hsa-miR-298 hsa-mir-298 20 VDR 7421 19581388
hsa-miR-298 hsa-mir-298 20 BACE1 23621 18986979
hsa-miR-298 hsa-mir-298 20 CDKN1A 1026 20190813
hsa-miR-298 hsa-mir-298 20 PAK3 5063 20190813
hsa-miR-298 hsa-mir-298 20 DICER1 23405 20375468
hsa-miR-214* hsa-mir-214 1 PTEN 5728 21228352
hsa-miR-214* hsa-mir-214 1 MYOD1 4654 19818710
hsa-miR-214* hsa-mir-214 1 CD28 940 20548023
hsa-miR-214* hsa-mir-214 1 NEUROG3 50674 18023200
hsa-miR-214* hsa-mir-214 1 AKT1 207 20400975
hsa-miR-214* hsa-mir-214 1 CALB1 793 21363966
hsa-miR-214* hsa-mir-214 1 VEGFA 7422 21080911
hsa-miR-214* hsa-mir-214 1 NOS3 4846 19733659
hsa-miR-214* hsa-mir-214 1 PTEN 5728 20548023
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Table 2 miRNAs that hit LMNA 3’UTR: their validated targets (Continued)
hsa-miR-214* hsa-mir-214 1 NBN 4683 18230126
hsa-miR-214* hsa-mir-214 1 CD44 960 20400975
hsa-miR-214* hsa-mir-214 1 EZH2 2146 21363966
hsa-miR-214* hsa-mir-214 1 ZNRD1 30834 21080911
hsa-miR-214* hsa-mir-214 1 APC 324 19701500
hsa-miR-214* hsa-mir-214 1 CDKN1A 1026 20534588
hsa-miR-214* hsa-mir-214 1 IKBKB 3551 20400975
hsa-miR-214* hsa-mir-214 1 PRNP 5621 21363966
hsa-miR-214* hsa-mir-214 1 MYC 4609 20716115
hsa-miR-214* hsa-mir-214 1 CTNNB1 1499 19701500
hsa-miR-214* hsa-mir-214 1 NRAS 4893 20534588
hsa-miR-214* hsa-mir-214 1 PTEN 5728 20400975
hsa-miR-214* hsa-mir-214 1 ENAM 10117 21363966
hsa-miR-214* hsa-mir-214 1 PAK1 5058 20716115
hsa-miR-214* hsa-mir-214 1 DCT 1638 19546168
hsa-miR-214* hsa-mir-214 1 ATP2A2 488 20498046
hsa-miR-214* hsa-mir-214 1 TWIST1 7291 20400975
hsa-miR-214* hsa-mir-214 1 MOCOS 55034 21358347
hsa-miR-214* hsa-mir-214 1 PTEN 5728 20716115
hsa-miR-214* hsa-mir-214 1 MYC 4609 19435428
hsa-miR-214* hsa-mir-214 1 CCND2 894 20498046
hsa-miR-214* hsa-mir-214 1 RAB22A 57403 20302635
hsa-miR-214* hsa-mir-214 1 COX8A 1351 21345725
hsa-miR-214* hsa-mir-214 1 ZEB1 6935 20716115
hsa-miR-214* hsa-mir-214 1 TGFBR2 7048 19435428
hsa-miR-214* hsa-mir-214 1 JUN 3725 20498046
hsa-miR-214* hsa-mir-214 1 TOP2B 7155 20219416
hsa-miR-214* hsa-mir-214 1 SOX9 6662 21288128
hsa-miR-214* hsa-mir-214 1 DICER1 23405 20716115
hsa-miR-214* hsa-mir-214 1 TACSTD1 4072 18589210
hsa-miR-214* hsa-mir-214 1 TCF3 6929 20498046
hsa-miR-214* hsa-mir-214 1 MAPK8 5599 19859982
hsa-miR-214* hsa-mir-214 1 EGFL7 51162 21288128
hsa-miR-214* hsa-mir-214 1 EIF2C1 26523 20716115
hsa-miR-214* hsa-mir-214 1 AKT1 207 18199536
hsa-miR-214* hsa-mir-214 1 KLF4 9314 20498046
hsa-miR-214* hsa-mir-214 1 MAP2K3 5606 19859982
hsa-miR-214* hsa-mir-214 1 ROBO2 6092 21276775
hsa-miR-214* hsa-mir-214 1 EIF2C2 27161 20716115
hsa-miR-214* hsa-mir-214 1 BIRC3 330 18199536
hsa-miR-214* hsa-mir-214 1 SH2B2 10603 20498046
hsa-miR-214* hsa-mir-214 1 EZH2 2146 19818710
hsa-miR-214* hsa-mir-214 1 SRGAP2 23380 21276775
hsa-miR-214* hsa-mir-214 1 RAG2 5897 20651252
hsa-miR-214* hsa-mir-214 1 PTEN 5728 18199536
hsa-miR-214* hsa-mir-214 1 STMN2 11075 20498046
hsa-miR-214* hsa-mir-214 1 AMELX 265 21363966
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Table 3 miRNAs validated targets, hierarchical order
Gene name Hits Gene name Hits Gene name Hits Gene name Hits Gene name Hits Gene name Hits Gene name Hits
DICER1 5 LIN28 2 CD46 1 G6PD 1 MAP2K3 1 POU2F2 1 SPI1 1
CDKN1A 4 MAPK8 2 CD47 1 GABPA 1 MAP3K12 1 POU4F2 1 SRGAP2 1
NFKB1 4 MECP2 2 CDC14A 1 GHRHR 1 MAP3K9 1 PPARG 1 ST3GAL4 1
TP53 4 MITF 2 CDC20B 1 GRB2 1 MAPK14 1 PPIG 1 STAT3 1
VEGFA 4 MYCN 2 CDC25C 1 GRIA1 1 MAPK3 1 PPP1R13L 1 STK39 1
APC 3 PAK3 2 CDC42 1 GRIN2A 1 MAPKAPK2 1 PRB1 1 STMN2 1
BCL2 3 PROM1 2 CDH1 1 GRIN2B 1 MCL1 1 PRDM1 1 SYNE1 1
CD44 3 PTEN 2 CDK4 1 GRM3 1 MDC1 1 PRKAR1A 1 TARBP2 1
CDC25A 3 SCPEP1 2 CDKN1B 1 GRM7 1 MDM2 1 PRMT5 1 TBK1 1
CDK6 3 SIRT1 2 CEBPB 1 GSX2 1 MDM4 1 PRNP 1 TCF21 1
EIF2C1 3 SOAT1 2 CHEK1 1 GULP1 1 MEIS2 1 PTPN12 1 TCF3 1
EIF2C2 3 SSSCA1 2 CHRD 1 HBEGF 1 MEST 1 PTPN13 1 TCL1A 1
HDAC9 3 STMN1 2 CISH 1 HDAC1 1 MET 1 PXMP2 1 TGFBR2 1
IL1B 3 TACSTD1 2 CKAP4 1 HDAC2 1 MGST1 1 RAB22A 1 TGIF2 1
KRAS 3 TLR4 2 CNN3 1 HELLS 1 MMP13 1 RAB34 1 TIMM8A 1
MYC 3 TP73 2 COL11A2 1 HES1 1 MOCOS 1 RAG2 1 TLR2 1
RNASEN 3 WNT1 2 COL2A1 1 HGF 1 MPI 1 RASSF1 1 TNRC6A 1
AKT1 2 ZEB1 2 COL9A1 1 HLCS 1 MYB 1 RB1 1 TOM1 1
ATN1 2 ACSL1 1 COMP 1 HMG2L1 1 MYBL1 1 RBBP6 1 TOP2B 1
BACE1 2 ACTB 1 CREBZF 1 HMOX1 1 MYD88 1 RCOR1 1 TRIM63 1
BCL6 2 AMELX 1 CRIM1 1 HNF4A 1 MYOD1 1 RELB 1 TRPM3 1
BDNF 2 ANLN 1 CSF1 1 HOXA5 1 NBN 1 REST 1 TWIST1 1
BIRC3 2 ANP32B 1 CTNNB1 1 HRB 1 NDRG1 1 RGS3 1 UBL4A 1
CCND1 2 ARCN1 1 CTNNBIP1 1 HUWE1 1 NDUFA2 1 RNMT 1 VAMP2 1
CCNE2 2 ARIH2 1 CXCL12 1 IGF1 1 NEUROD1 1 RNPC3 1 VDR 1
CDKN2A 2 ATF6 1 CYP2A6 1 IGFALS 1 NEUROG3 1 ROBO2 1 WEE1 1
CDKN2D 2 ATP2A2 1 CYP3A4 1 IKBKB 1 NF2 1 ROS1 1 WISP2 1
CEBPA 2 ATP6V1B2 1 DCT 1 IL2RA 1 NFE2L2 1 RPE 1 XPO5 1
COX8A 2 AXIN2 1 DDIT3 1 IL7R 1 NFYC 1 RPS19 1 YY1 1
CREB1 2 BAMBI 1 DDIT4 1 ING2 1 NOG 1 RTEL1 1 ZAP70 1
DDX20 2 BAX 1 DDX4 1 IRAK1 1 NOL3 1 RUNX1 1 ZEB2 1
DGCR8 2 BBC3 1 DKK2 1 IRAK2 1 NOS2A 1 RUNX2 1 ZNF135 1
E2F1 2 BCR 1 DLL1 1 IRF1 1 NOS3 1 RUNX3 1 ZNF77 1
E2F3 2 BNIP3L 1 DNMT1 1 IRF9 1 NOTCH1 1 SEC24D 1 ZNF828 1
E2F5 2 BRAP 1 ECD 1 IRS1 1 NPAT 1 SEMA6A 1 ZNRD1 1
ELSPBP1 2 BRCA1 1 EDG6 1 JAG1 1 NPC1 1 SERPINE1 1
EPHB2 2 C1orf183 1 EGFL7 1 JARID1B 1 NR1H4 1 SFRP1 1
ERBB2 2 C1orf61 1 EGFR 1 KCNMA1 1 NR2E1 1 SFRS2 1
EZH2 2 C9orf127 1 EIF2C4 1 KIF23 1 NRAS 1 SH2B2 1
FASN 2 CALB1 1 ELAVL1 1 KIT 1 NTRK3 1 SLC11A1 1
FOXO1 2 CAV1 1 ELAVL2 1 LAMC2 1 OCA2 1 SLC12A1 1
FOXP1 2 CBX7 1 ELK3 1 LARP4 1 PAK1 1 SLC22A3 1
FRAP1 2 CCND2 1 ENAM 1 LARP6 1 PAWR 1 SLC27A4 1
GEMIN4 2 CCND3 1 ERBB4 1 LEF1 1 PAX6 1 SLC2A1 1
HMGA2 2 CCNE1 1 ETS1 1 LIF 1 PDGFA 1 SLC7A5 1
IFNG 2 CCNF 1 FGF8 1 LMX1A 1 PEA15 1 SMARCA5 1
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Table 3 miRNAs validated targets, hierarchical order (Continued)
IL6 2 CCPG1 1 FMR1 1 LOX 1 PHGDH 1 SND1 1
JAK2 2 CD19 1 FOXG1 1 LRPAP1 1 PIK3CA 1 SOCS1 1
JUN 2 CD28 1 FOXJ1 1 MAP1LC3A 1 PIWIL1 1 SOX2 1
KLF4 2 CD4 1 FZR1 1 MAP2K1 1 PMP22 1 SOX9 1
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as LMNA ceRNAs. The maximum number of hits is 5.
Genes that share in their transcripts 3 to 5 validated
microRNAs with the predicted microRNAs with the
3’UTR of the longest LMNA transcript were arbitrarily
considered as potential ceRNAs for further analyses. 17
genes have these characteristics out of a total of 335.
These 17 genes were analysed using the GeneMANIA
[16] tool that helps to predict the functions of a set of
genes and to predict in which Gene Ontology (GO)
functions the set of genes might be involved. The results
are reported in Table 4. Table 4 also shows the GO
functions from the ones with the lowest False Discovery
Rate (FDR) till a FDR < 0.1. All analyses were updated to
September 13th 2012.
Results and discussion
A ceRNA analysis might reveal genes that are co-regulated
post-transcriptionally and that can be functionally corre-
lated [13]. The 3’UTR of the longest transcript of the
LMNA human gene was selected for the analysis because
the vast majority of miRNAs recognize and regulate the
efficiency of transcription by binding to this portion of
messenger RNAs [13]. Moreover, the 3’UTR of the longest
transcript is shared between Lamin-A and progerin splicing
form, and it is different form the shorter 3’UTR of the
Lamin-C transcript, not used in this study. The miRWalk
database and tools [14] were used to perform the analysis.
The database reported no validated miRNAs that bind to
the 3’UTR of the main transcript of the LMNA gene. By
contrast, in this study, predicted miRNAs able to bind to
the 3’UTR of the main transcript of the LMNA gene were
used. The predicted miRNAs are shown in Table 1.
Although the database does not report any validated
miRNAs, it is to be noted that miR-9, one of the predicted
miRNAs isolated, has recently been validated [17].
Amongst the isolated miRNAs worth noting is miR-214,
clearly involved in cancer and stemness [18,19]; miR-9,
involved in neurogenesis [20] and, very interestingly,
protective in neural cells of HGPS patients against the
effects of progeria [21]; miR-298, involved in the regulation
of beta-amyloid precursor protein converting enzyme mes-
senger RNA translation, and thus in Alzheimer’s disease
[22]; the tumour suppressor miR-34a [23]; and miR-449a
involved in differentiation [24] and pRB mediated cell cycle
arrest [25].The correlation of the expression levels of LMNA and
each miRNA was analysed using the mimiRNA software
[15], which allows one to compare the expression
profiles reported in different human tissues and cell lines.
The data are reported in Table 1. One should expect a
negative correlation between a miRNA and its regulated
genes. Only 9 of the 11 miRNAs isolated could be analysed
using the mimiRNA software; and amongst them 6 out
of 9 showed a negative correlation, as expected, with the
exception of miR-214, miR-24a and miR-532-3p.
The miRNAs in Table 1 were used as baits to find any
human gene whose 3’ UTRs are recognized by them as
literature validated targets, again using the miRWalk
database and tools [14]. 670 couples of bait miRNA-gene
were recovered. They are reported in Table 2.
Following the ceRNA hypothesis, the more miRNA
were shared between the transcripts 3’UTRs, the stronger
their interaction could be. The data reported in Table were
organized on the basis of the quantity of miRNA reported
in Table 1 able to hit the transcripts from each gene.
Multiple hits from the same miRNA on the same gene
were weighted as unique. Genes were then organized from
the most hit to the less hit.
The results shown in Table 3 show only one gene
transcript hit 5 times (DICER1); 4 gene transcripts hit
4 times (CDKN1A, NFKB1, TP53, VEGFA); 12 gene
transcripts hit 3 times (APC, BCL2, CD44, CDC25A,
CDK6, EIF2C1, EIF2C2, HDAC9, IL1B, KRAS, MYC,
RNASEN); 51 gene transcripts hit 2 times; and 267
gene transcripts hit only once.
Arbitrarily, further analyses were performed focusing
on genes whose transcripts were hit from 3 to 5 times,
because they more likely constitute ceRNAs for the
LMNA transcripts. This choice was made because the
higher the number of shared miRNAs, the higher the
possibility that the discovered genes could act as ceRNAs.
Using genes that are hit by few miRNAs could raise the
risk of picking up false positives. Unfortunately, no
standardization can be used on the basis of previously
published data. The cut-off point was chosen taking into
account ceRNAs recognized by more than 50% of miR-
NAs of the most hit genes: specifically genes hit by more
than 2.5 miRNAs, that is 3 to 5 miRNAs, as stated. Of
course this arbitrary decision could have affected the
subsequent analyses, increasing the risk of false negatives,
but a highly stringent strategy was preferred, taking the




post-transcriptional gene silencing by RNA 8.71E-4
gene silencing by miRNA 8.71E-4
post-transcriptional gene silencing 8.71E-4
cellular response to abiotic stimulus 1.11E-3
response to abiotic stimulus 1.11E-3
gene silencing by RNA 1.11E-3
production of miRNAs involved in gene silencing by miRNA 2.64E-3
cell ageing 2.64E-3
cyclin-dependent protein kinase holoenzyme complex 2.64E-3
dsRNA fragmentation 2.8E-3
production of small RNA involved in gene silencing by RNA 2.8E-3
gene silencing 3.84E-3
regulation of homeostatic process 3.84E-3
ageing 3.84E-3
regulation of cyclin-dependent protein kinase activity 3.84E-3
regulation of cell motility 4.01E-3
cellular response to dsRNA 4.29E-3
regulation of protein serine/threonine kinase activity 4.61E-3
regulation of cellular component movement 4.61E-3
regulation of locomotion 4.61E-3
response to dsRNA 4.94E-3
positive regulation of protein phosphorylation 7.51E-3
response to radiation 8.64E-3
cellular response to hypoxia 8.97E-3
cellular senescence 9.78E-3
positive regulation of phosphorylation 9.95E-3
positive regulation of phosphorus metabolic process 1.02E-2
response to drug 1.02E-2
positive regulation of phosphate metabolic process 1.02E-2
cellular response to oxygen levels 1.02E-2
RNA helicase activity 1.12E-2
vascular endothelial growth factor receptor
signaling pathway
1.74E-2
Ras guanyl-nucleotide exchange factor activity 1.74E-2
positive regulation of endothelial cell migration 1.8E-2
regulation of gene expression, epigenetic 1.8E-2
cellular response to radiation 2.08E-2
regulation of cell migration 2.15E-2




positive regulation of angiogenesis 4.47E-2
cellular response to external stimulus 4.49E-2
small GTPase mediated signal transduction 4.49E-2
positive regulation of cell migration 4.49E-2
regulation of endothelial cell migration 4.59E-2
Table 4 Putative LMNA ceRNAs GO functions (Continued)
positive regulation of cell motility 4.6E-2
positive regulation of cell adhesion 4.94E-2
positive regulation of locomotion 5.07E-2
positive regulation of cellular component movement 5.1E-2




positive regulation of vascular endothelial growth
factor receptor signaling pathway
5.53E-2
cyclin-dependent protein kinase activity 5.53E-2
positive regulation of protein modification process 6.09E-2
helicase activity 7.11E-2
G1/S transition of mitotic cell cycle 7.19E-2
regulation of chromosome organization 7.19E-2
regulation of cell aging 7.38E-2
positive regulation of peptidyl-tyrosine phosphorylation 8.34E-2
regulation of vascular endothelial growth factor
receptor signaling pathway
8.42E-2
ncRNA metabolic process 9.24E-2
endonuclease activity, active with either ribo- or
deoxyribonucleic acids and producing
5'- phosphomonoesters
9.24E-2
regulation of cellular response to growth factor stimulus 9.24E-2
angiogenesis 9.24E-2
endothelial cell migration 9.59E-2
response to hypoxia 9.59E-2
response to oxygen levels 9.92E-2
cellular response to UV 9.92E-2
Cell migration involved in sprouting angiogenesis 9.92E-2
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literature the analysis of these 17 genes strikingly
highlights a possible relationship between LMNA gene
functions and RNA interference machinery: DICER1,
EIF2C1, EIF2C2 and RNASEN code respectively for Dicer,
Argonaute1, Argonaute2 and Drosha, the key effectors of
the RNA interference machinery [26]. Interestingly, there
are no data reporting a relationship between Lamin-A and
RNA interference machinery. Another network involved
in LMNA functions is p53 and the control of cell cycle:
TP53 coding for p53 itself, while CDKN1A, CDC25A and
CDK6 code respectively for p21, the phosphatase
CDC25A and the cyclin-dependent protein kinase 6,
differently expressed during the cell cycle and involved in
bypassing the G1/S checkpoint. p53 directly regulates p21
[27] and CDC25A [28] which indirectly regulates the
cyclin-dependent protein kinase 6 [29]. Notably, the
expression of TP53, APC, BCL2, KRAS and MYC is very
often altered in several types of human cancer [30-34].
Interestingly, clear involvement of LMNA mutations in
the control of cell cycle and in cancer has been reported
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inflammation and cancer-related inflammation and
angiogenesis [36-38]. It is worth noting that coronary
artery atherosclerosis typically leads to the death of
HGPS patients [39] and that LMNA mutations have
been linked to inflammatory myopathy [40]. Notably, it
has been suggested that the splicing factor SRSF1 may
have a role in driving alternative splicing forms of both
LMNA and VEGFA during the senescence of endothelial
cells [41].
HDAC9 codes for a histone deacetylase, a class of the
epigenetic covalent modifiers, involved in the risk of
ischemic stroke [42]. It has been reported that Lamin-A/C
deficiency causes chromosome condensation that can be
reversed by histone acetylase inhibitors [43].
CD44 codes for a surface marker of hematopoietic stem
and progenitor cells and is also involved in cancer [44].
With the aim of analysing the 17 putative ceRNAs
isolated, the GeneMANIA [16] tool was used. It helps to
predict the functions of a set of genes and to predict in
which Gene Ontology (GO) functions they might be
involved. The results are reported in Table 4 from the most
statistically significant to the less, up to a False Discovery
Rate (FDR) < 0.1. Interestingly, posttranscriptional gene
silencing by RNA, ageing, cellular senescence, G1/S transi-
tion of mitotic cell cycle and angiogenesis are all statistically
significant, amongst many other GO functions.
It is to be noted that in a previous study [2] the
authors used the predicted miRNAs that hit the 3’UTR
of the longest transcript of the LMNA gene to find any
human gene whose 3’ UTRs are recognized by them as
predicted targets, not literature validated ones as in the
present study, again using the miRWalk database and
tools [14]. Moreover, in that study the GeneMANIA [16]
tool was also used together with the Osprey visualization
tool [45] of the BioGRID database [46]. The result of
that study highlighted a central role of RB1 and HTA-
TIP genes, possible involvement in prostate cancer,
and a possible role of LMNA in epigenetic modifica-
tion, especially acetylation events, and ATP dependent
chromatin remodelling via the chromatin remodelling
complexes PBAF and SWI/SNF. Taken together, these
studies suggest a possible role of LMNA gene products
in the control of cell cycle and tumorigenesis, chromatin
remodelling, epigenetic modifications, especially acetylation
via HTATIP/HDAC9, and a close link with the RNA
interference machinery.
Conclusion
In HGPS there is accumulation in the nuclear membrane
of the Lamin-A rare splicing form called progerin. How
the accumulation of progerin leads to progeria is still
under debate. The aim of this article was to investigate the
network of interactions of LMNA gene to find candidategenes and gene ontology functions involved in Lamin-A
functions and in turn possibly perturbed in progeria. To
search for possible partners of the LMNA gene involved
in HGPS and normal ageing, bioinformatics analyses of
the network of interactions of the Lamin-A/progerin were
performed looking for LMNA ceRNAs using Lamin-A/
progerin 3’UTR as a bait. The analysis might be quite
useful because it allows one to isolate possible interactors
for the gene being examined and to discover novel
functions in which it might be involved.
LMNA is mutated in several human diseases of genetic
origin with very variable phenotypes, suggesting a multiple
role of LMNA gene products in cell homeostasis and func-
tions [47,48]. There have been reported laminopathies due
to LMNA mutations such as Emery-Dreifuss muscular dys-
trophy, familial partial lipodystrophy, limb girdle muscular
dystrophy, dilated cardiomyopathy, Charcot-Marie-Tooth
disease, and Hutchinson-Gilford progeria syndrome, which
is the main focus of this study. This study might help to
understand why different mutations of a single gene can
induce many different phenotypes in affected patients. The
wide range of functions possibly involved in the LMNA
network of interactions can give a plausible explanation of
the many phenotypes due to LMNA mutations in humans.
The possible involvement of LMNA in the network of
regulation of key cellular functions such as control of
the cell cycle, epigenetics and chromatin remodelling,
and RNA interference highlights a central role of Lamins
in the nuclear functions. Further studies are required to
better understand the relationship between LMNA pro-
ducts and the cellular components isolated, but a better
understanding of the LMNA network might improve the
quality of life of many patients affected by laminopathies.
It might also enhance our comprehension of how the
structural components and the functional components
of the eukaryote nuclei interact.
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